Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
Company Announcements
Basilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 2025
2d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
6d ago
Premium
Company Announcements
Basilea Pharmaceutica Expands Pipeline with New Antibiotic License
7d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
8d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
12d ago
Premium
Company Announcements
Basilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors
12d ago
Premium
Company Announcements
Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections
14d ago
Premium
Ratings
Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation
16d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Fosmanogepix Study: A Potential Game-Changer in Antifungal Treatment
19d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments
21d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Fosmanogepix: A New Hope for Drug-Resistant Fungal Infections
27d ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment
1M ago
Premium
Company Announcements
Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment
1M ago
Premium
Ratings
Basilea Pharmaceutica Receives Buy Rating Backed by U.S. Government Funding and Promising Drug Developments
1M ago
Premium
Company Announcements
Basilea Secures $39 Million BARDA Funding for Antifungal Drug Development
1M ago
Premium
Company Announcements
Basilea Pharmaceutica’s Fosmanogepix Study: A Potential Game-Changer in Pharma
2M ago
Premium
Ratings
Buy Rating for Basilea Pharmaceutica Driven by Cresemba’s Global Success and Zevtera’s U.S. Rollout
2M ago
Premium
Ratings
Positive Outlook for Basilea Pharmaceutica: Buy Rating Backed by Strong Product Launches and Market Position
3M ago
Premium
Ratings
Basilea Pharmaceutica: Strong Buy Rating Backed by Zevtera’s U.S. Launch and Robust Financial Outlook
5M ago
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
